LDL-Apheresis: Technical and Clinical Aspects [PDF]
The Scientific World Journal, 2012 The prognosis of patients suffering from severe hyperlipidemia, sometimes combined with elevated lipoprotein (a) levels, and coronary heart disease refractory to diet and lipid-lowering drugs is poor. For such patients, regular treatment with low-density
Rolf Bambauer +4 more
doaj +8 more sources
LDL apheresis as an alternate method for plasma LPS purification in healthy volunteers and dyslipidemic and septic patients [PDF]
Journal of Lipid Research, 2020 Lipopolysaccharide (LPS) is a key player for innate immunity activation. It is therefore a prime target for sepsis treatment, as antibiotics are not sufficient to improve outcome during septic shock.
Auguste Dargent +12 more
doaj +5 more sources
LDL Apheresis and Lp (a) Apheresis: A Clinician's Perspective. [PDF]
Curr Atheroscler Rep, 2021 Lipoprotein apheresis is the most effective means of lipid-lowering therapy. However, it's a semi-invasive, time consuming, and chronic therapy with variable adherence. There are still no specific guideline recommendations for the management of patients on lipid apheresis.
Kayikcioglu M.
europepmc +6 more sources
LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: relevance to atheroprotection [PDF]
Journal of Lipid Research, 2011 Subnormal HDL-cholesterol (HDL-C) and apolipoprotein (apo)AI levels are characteristic of familial hypercholesterolemia (FH), reflecting perturbed intravascular metabolism with compositional anomalies in HDL particles, including apoE enrichment. Does LDL-
Alexina Orsoni +10 more
doaj +3 more sources
HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia. [PDF]
PLoS ONE, 2014 BACKGROUND:Pentraxin 3 (PTX3), a key component of the humoral arm of innate immunity, is secreted by vascular cells in response to injury, possibly aiming at tuning arterial activation associated with vascular damage.
Michela Zanetti +11 more
doaj +3 more sources
Platelet aggregation and lipoprotein levels in a patient with familial hypercholescholesterolemia after selective LDL-apheresis [PDF]
São Paulo Medical Journal, 1997 Platelet aggregation was studied in a patient with familial hypercholesterolemia immediately after aphereis selective for low-density lipoprotein (LDL), a lipid-lowering procedure.This treatment reduced plasmatic levels of total and LDL-cholesterol, apo ...
Madalena Nunes da Silva Pares +4 more
doaj +2 more sources
Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia[S] [PDF]
Journal of Lipid Research, 2014 Lipoprotein-apheresis (apheresis) removes LDL-cholesterol in patients with severe dyslipidemia. However, reduction is transient, indicating that the long-term cardiovascular benefits of apheresis may not solely be due to LDL removal. Microparticles (MPs)
Katherine D. Connolly +8 more
doaj +3 more sources
Journal of Lipid Research, 2000 Epidemiologic studies and in vitro experiments indicate that low density lipoprotein (LDL) subtypes differ concerning their atherogenic potential. Small, dense LDL are more atherogenic than large, buoyant LDL.
B.M. Schamberger +4 more
doaj +2 more sources
Management of Pregnancy in a Patient with Familial Hypercholesterolemia and Previous Myocardial Infarction—Treatment with LDL Apheresis: A Case Report [PDF]
ReportsFamilial hypercholesterolemia, a genetic disorder marked by elevated low-density lipoprotein cholesterol (LDL-C), poses significant risks for premature atherosclerosis and cardiovascular diseases, particularly during pregnancy. One of the safe methods of
Milos Milincic +6 more
doaj +2 more sources
Journal of Lipid Research, 1996 Apheresis is a treatment option for patients with severe hypercholesterolemia and coronary artery disease. It is, however, unknown whether such therapy changes kinetic parameters of lipoprotein metabolism, such as apolipoprotein B (apoB) secretion rates,
K G Parhofer +4 more
doaj +2 more sources